Clinical trial
Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes…
NCT00328172 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00328172 |
|---|---|
| Title | Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients |
| Official title | A Randomized, Double-blind, Placebo-controlled, Five Parallel Group Study Investigating the Efficacy and Safety of BI 1356 BS (0.5 mg, 2.5 mg and 5.0 mg Administered Orally Once Daily) Over 12 Weeks in Drug Naive and Treated Patients With Type 2 Diabetes With Insufficient Glycemic Control (Study… |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | Placebo, BI 1356 dose 3 once daily, BI 1356 dose 2 once daily, BI 1356 dose 1 once daily, Metformin |
| Enrollment | 302 |
| Start date | May 1, 2006 |
| Primary completion | Aug 1, 2007 |
| First posted | May 19, 2006 |
| Last update posted | Mar 14, 2014 |
| Countries | Australia, Canada, Czechia, Russia, Ukraine, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: